Sarah Cannon
June 01, 2015

NASHVILLE, TENN., June 1, 2015 Oncology Hematology Care (OHC) received the Conquer Cancer Foundation’s American Society of Clinical Oncology (ASCO) Clinical Trials Participation Award (CTPA) on Sunday during the 51st ASCO® Annual Meeting. OHC, a community-based oncology practice in Cincinnati, Ohio, is a strategic investigator site for Sarah Cannon Research Institute, the research arm of HCA’s global cancer institute, Sarah Cannon. Over the last decade, OHC has partnered with SCRI to provide cutting-edge clinical trials to patients in a community setting.

“OHC is a proven leader with exceptional patient enrollment and improvement initiatives that have consistently upheld our rigorous safety standards when designing and conducting clinical trials,” said SCRI Chief Medical Officer Howard A. “Skip” Burris III, MD. “We look forward to continuing our work with OHC’s research leadership team as we advance therapies for patients.”

Created by ASCO®’s Clinical Trials Task Force in 2001, the CTPA was designed to recognize high-quality clinical research sites and increase the awareness of and participation in clinical trials among physicians. This is the second time OHC has won the award.

In collaboration with Sarah Cannon Research Institute, OHC has participated in investigator initiated clinical trials as well as sponsor trials, resulting in more than 600 early- and late-phase study patients enrolled over the last three years. The site complies with the International Conference on Harmonization (ICH) Good Clinical Practice (GCP) guidelines and has embraced the eight attributes of an exemplary research site that exceed the GCP criteria. Additionally, OHC has increased opportunities for research diversification including internal educational strategies to enhance screening and direct patient education in its programs.

“We are thrilled to accept the CTPA this year at ASCO®,” said David M. Waterhouse, M.D., M.P.H., principal investigator and chief of the Clinical Trial Research Department at OHC. “As one of the largest private practices conducting clinical research in the country, OHC is committed to being at the forefront of the latest developments in treatments for cancer patients. With our strategic partner, Sarah Cannon Research Institute, OHC provides patients in our community with convenient access to novel therapies.”

About Sarah Cannon Research Institute

Sarah Cannon Research Institute is the research arm of HCA’s global cancer institute, Sarah Cannon. Focused on advancing therapies for patients, it is one of the world’s leading clinical research organizations conducting community-based clinical trials in oncology, cardiology and orthopedics through affiliations with a network of more than 1,000 physicians across the United States and United Kingdom. Sarah Cannon Research Institute has led more than 170 first-in-man clinical trials since its inception in 1993, and has been a clinical trial leader in nearly 80 percent of approved cancer therapies in the last 10 years. Additionally, Sarah Cannon Research Institute offers management, regulatory, and other research support services for drug development and industry sponsors as well as strategic investigator sites through its contract research organization (CRO), SCRI Development Innovations. For more information, visit

About Oncology Hematology Care, Inc.

For 30 years, OHC (Oncology Hematology Care, Inc.) has served as the region’s premier provider of treatments for cancer and blood disorders, offering a wide range of services, state-of-the-art treatments and technologies. OHC puts patients first by delivering leading-edge, compassionate and convenient care, tailored to meet a patient’s medical and personal needs. With more than 40 physicians and advanced practice providers, OHC treats nearly every form of cancer and complex blood disorders with medical, radiation and gynecologic oncology specialists. OHC also offers clinical research trials in cutting-edge protocols, and the most experienced adult blood and marrow transplant center in Cincinnati.